MMRGlobal Adds Japan & South Korea to China in Filing of Cancer Fighting Patent Under Expedited Patent Allowance Program

MMRGlobal Adds Japan & South Korea to China in Filing of Cancer Fighting Patent Under Expedited Patent Allowance Program

LOS ANGELES, CA — (Marketwired) — 08/26/13 — (OTCQB: MMRF) ("MMR"), a leading provider of (PHRs), storage solutions and electronic document management and imaging systems for , today announced that as a result of the Expedited Patent Allowance Program referred to as the Patent Prosecution Highway ("PPH"), and following the issuance of U.S. patents to MMR for its anti-CD20 monoclonal antibodies, the Company has received confirmation of the filings of a divisional applic

MMRGlobal Files Additional Cancer Fighting Patent in China Under Expedited Patent Allowance Program

MMRGlobal Files Additional Cancer Fighting Patent in China Under Expedited Patent Allowance Program

LOS ANGELES, CA — (Marketwired) — 08/19/13 — (OTCQB: MMRF) ("MMR"), a leading provider of (PHRs), storage solutions and electronic document management and imaging systems for , today announced that as a result of China-s participation in the Patent Prosecution Highway Program and the issuance of patents to MMR for its anti-CD20 monoclonal antibodies in the U.S., the Company has received confirmation from China of the filing on August 15, 2013 of a divisional Chinese patent appli

MMRGlobal Announces U.S. Patent for Cancer Fighting Anti-CD20 Monoclonal Antibody

MMRGlobal Announces U.S. Patent for Cancer Fighting Anti-CD20 Monoclonal Antibody

LOS ANGELES, CA — (Marketwired) — 04/15/13 — (OTCQB: MMRF) ("MMR") today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for the Company-s anti-CD20 monoclonal antibody assets, U.S. Serial No. 11/855,943, under the title, "Antibodies and Methods for Making and Using Them." This is the first U.S. patent to be granted for the Company-s anti-CD20 monoclonal antibodies, which have particular utility in fighting cancers. The anti-